FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038260033> ?p ?o ?g. }

• W2038260033 endingPage "34147" @default.
• W2038260033 startingPage "34141" @default.
• W2038260033 abstract "The immediate-early gene cyclooxygenase 2 (Cox-2) is induced in a variety of hyperplastic pathological conditions, including rheumatoid arthritis and colorectal cancer. Although a causal role for Cox-2 has been proposed, mechanisms by which Cox-2 function contributes to the pathogenesis of hyperplastic disease are not well defined. We constructed a green fluorescent protein-tagged Cox-2 (Cox-2-GFP) to examine its effects on a variety of cell types upon overexpression. Subcellular localization and enzymatic and pharmacological properties of Cox-2-GFP polypeptide were indistinguishable from those of the wild-type Cox-2 polypeptide. Overexpression of the Cox-2-GFP or the Cox-2 polypeptide by transient transfection suppressed the population of cells in the S phase of the cell cycle, with a concomitant increase in G0/G1 population. In contrast, transient overexpression of GFP had no effect on cell cycle distribution, whereas endoplasmic reticulum-retained GFP (GFP-KDEL) overexpression was associated with only a minor decrease of cells in S phase. Interestingly, neither NS-398 (a Cox-2-specific inhibitor) nor indomethacin could reverse the effect of Cox-2-GFP overexpression on cell cycle progression. Furthermore, two mutants of Cox-2, S516Q and S516M, which lack the cyclooxygenase activity, exhibited the same effect as Cox-2-GFP. The cell cycle effect of Cox-2-GFP was observed in ECV-304, NIH 3T3, COS-7, bovine microvascular endothelial cells, and human embryonic kidney 293 cells. These findings suggest that Cox-2 inhibits cell cycle progression in a variety of cell types by a novel mechanism that does not require the synthesis of prostaglandins. The immediate-early gene cyclooxygenase 2 (Cox-2) is induced in a variety of hyperplastic pathological conditions, including rheumatoid arthritis and colorectal cancer. Although a causal role for Cox-2 has been proposed, mechanisms by which Cox-2 function contributes to the pathogenesis of hyperplastic disease are not well defined. We constructed a green fluorescent protein-tagged Cox-2 (Cox-2-GFP) to examine its effects on a variety of cell types upon overexpression. Subcellular localization and enzymatic and pharmacological properties of Cox-2-GFP polypeptide were indistinguishable from those of the wild-type Cox-2 polypeptide. Overexpression of the Cox-2-GFP or the Cox-2 polypeptide by transient transfection suppressed the population of cells in the S phase of the cell cycle, with a concomitant increase in G0/G1 population. In contrast, transient overexpression of GFP had no effect on cell cycle distribution, whereas endoplasmic reticulum-retained GFP (GFP-KDEL) overexpression was associated with only a minor decrease of cells in S phase. Interestingly, neither NS-398 (a Cox-2-specific inhibitor) nor indomethacin could reverse the effect of Cox-2-GFP overexpression on cell cycle progression. Furthermore, two mutants of Cox-2, S516Q and S516M, which lack the cyclooxygenase activity, exhibited the same effect as Cox-2-GFP. The cell cycle effect of Cox-2-GFP was observed in ECV-304, NIH 3T3, COS-7, bovine microvascular endothelial cells, and human embryonic kidney 293 cells. These findings suggest that Cox-2 inhibits cell cycle progression in a variety of cell types by a novel mechanism that does not require the synthesis of prostaglandins. cyclooxygenase arachidonic acid 5-bromo-2′-deoxyuridine endoplasmic reticulum fluorescent-activated cell sorting green fluorescent protein hydroxyeicosatetraenoic acid prostaglandin propidium iodide PBS, phosphate-buffered saline human embryonic kidney cells Cyclooxygenase is the rate-limiting enzyme in the production of prostaglandins and thromboxanes, which are involved in numerous physiologic and pathologic processes such as inflammation, pain, angiogenesis, and the regulation of vascular tone. The Cox1 isoenzymes (the “constitutive” Cox-1 and the “inducible” Cox-2) have both overlapping as well as distinct physiologic and pathologic functions (1Dubois R.N. Abramson S.B. Crofford L. Gupta R.A. Simon L.S. Van De Putte L.B. Lipsky P.E. FASEB J. 1998; 12: 1063-1073Crossref PubMed Scopus (2225) Google Scholar, 2Hla T. Ristimaki A. Appleby S. Barriocanal J.G. Ann. N. Y. Acad. Sci. 1993; 696: 197-204Crossref PubMed Scopus (159) Google Scholar). They have similar subcellular localization in the ER and on the inner and outer membranes of the nuclear envelope (3Spencer A.G. Woods J.W. Arakawa T. Singer I.I. Smith W.L. J. Biol. Chem. 1998; 273: 9886-9893Abstract Full Text Full Text PDF PubMed Scopus (295) Google Scholar). The Cox enzymes catalyze two distinct reactions: 1) the conversion of AA to PGG2 via the cyclooxygenase activity and 2) the reduction of PGG2 to PGH2 via the peroxidase activity. PGH2 is converted by distinct isomerases into biologically active prostaglandins, including PGD2 and PGE2. Nonsteroidal anti-inflammatory drugs such as aspirin and indomethacin inhibit the cyclooxygenase activity but not the peroxidase activity (4Smith W.L. DeWitt D.L. Dixon F.J. Advances in Immunology. 62. Academic Press, Orlando, FL1996: 167-215Google Scholar,5Laneuville O. Breuer D.K. Dewitt D.L. Hla T. Funk C.D. Smith W.L. J. Pharmacol. Exp. Ther. 1994; 271: 927-934PubMed Google Scholar). Recently developed Cox-2-specific inhibitors such as NS-398, celecoxib (SC-58635), and rofecoxib likewise inhibit the cyclooxygenase activity of the Cox-2 isoenzyme and thus inhibit prostanoid synthesis (6Warner T.D. Giuliano F. Vojnovic I. Bukasa A. Mitchell J.A. Vane J.R. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 7563-7568Crossref PubMed Scopus (1424) Google Scholar). Most biologically active prostanoids act on plasma membrane-localized G-protein-coupled receptors (7Coleman R.A. Smith W.L. Narumiya S. Pharmacol. Rev. 1994; 46: 205-229PubMed Google Scholar). Some prostanoids, such as 15-deoxy-12,14-PGJ2, act via the nuclear peroxisomal proliferator activator receptors (8Forman B.M. Tontonoz P. Chen J. Brun R.P. Spiegelman B.M. Evans R.M. Cell. 1995; 83: 803-812Abstract Full Text PDF PubMed Scopus (2731) Google Scholar, 9Kliewer S.A. Lenhard J.M. Willson T.M. Patel I. Morris D.C. Lehmann J.M. Cell. 1995; 83: 813-819Abstract Full Text PDF PubMed Scopus (1869) Google Scholar). Overexpression of Cox-2 is associated with a variety of proliferative diseases, such as rheumatoid arthritis, colorectal cancer, and gastric cancer (1Dubois R.N. Abramson S.B. Crofford L. Gupta R.A. Simon L.S. Van De Putte L.B. Lipsky P.E. FASEB J. 1998; 12: 1063-1073Crossref PubMed Scopus (2225) Google Scholar, 2Hla T. Ristimaki A. Appleby S. Barriocanal J.G. Ann. N. Y. Acad. Sci. 1993; 696: 197-204Crossref PubMed Scopus (159) Google Scholar). Cox-2-selective inhibitors may be chemopreventive in colorectal cancer development (10Kawamori T Rao C.V. Seibert K. Reddy B.S. Cancer Res. 1998; 58: 409-412PubMed Google Scholar, 11Sheng H. Shao J. Kirkland S.C. Isakson P. Coffey R.J. Morrow J. Beauchamp R.D. DuBois R.N. J. Clin. Invest. 1997; 99: 2254-2259Crossref PubMed Scopus (699) Google Scholar). Furthermore, gene deletion studies show that Cox-2 is required for the adenomatosus polyposis coli model of colorectal cancer development in mice (12Oshima M. Dinchuk J.E. Kargman S.L. Oshima H. Hancock B. Kwong E. Trzaskos J.M. Evans J.F. Taketo M.M. Cell. 1996; 87: 803-809Abstract Full Text Full Text PDF PubMed Scopus (2282) Google Scholar). Although these data strongly suggest a causal role for Cox-2 in proliferative diseases, relevant molecular mechanisms are not well defined. Overexpression of Cox-2 in an intestinal epithelial cell line is associated with inhibition of apoptosis, which may be a potential mechanism for tumorigenesis (13Tsujii M. DuBois R.N. Cell. 1995; 83: 493-501Abstract Full Text PDF PubMed Scopus (2137) Google Scholar). Cox-2 overexpression in a colorectal cancer cell line was also shown to stimulate the production of angiogenic factors such as vascular endothelial cell growth factor (14Tsujii M. Kawano S. Tsuji S. Sawaoka H. Hori M. DuBois R.N. Cell. 1998; 93: 705-716Abstract Full Text Full Text PDF PubMed Scopus (2214) Google Scholar). It is generally believed that overexpression of Cox-2 leads to the secretion of prostanoids and that interaction of these secreted prostanoids with membrane receptors triggers the proliferative and/or angiogenic effects (2Hla T. Ristimaki A. Appleby S. Barriocanal J.G. Ann. N. Y. Acad. Sci. 1993; 696: 197-204Crossref PubMed Scopus (159) Google Scholar, 15Hla T. Bishop-Bailey D. Liu C.H. Schaefer H. Trifan O.C. Int. J. Biochem. Cell Biol. 1999; 31: 551-557Crossref PubMed Scopus (190) Google Scholar). However, Cox isoenzymes possess a separate peroxidase activity that can modulate other cellular signaling pathways such as NFκB (16Munroe D.G. Wang E.Y. MacIntyre J.P. Tam S.S. Lee D.H. Taylor G.R. Zhou L. Plante R.K. Kazmi S.M. Bauerle P.A. Lau C. J. Inflamm. 1995; 45: 260-268PubMed Google Scholar). We recently showed that overexpression of Cox-1 resulted in the tumorigenic transformation of ECV-304 cells, an effect that was not inhibited by indomethacin (17Narko K. Ristimaki A. MacPhee M. Smith E. Haudenschild C.C. Hla T. J. Biol. Chem. 1997; 272: 21455-21460Crossref PubMed Scopus (95) Google Scholar). Simmons and co-workers (18Ballif B.A. Mincek N.V. Barratt J.T. Wilson M.L. Simmons D.L. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 5544-5549Crossref PubMed Scopus (80) Google Scholar) show that the Cox-2 protein binds to an apoptosis- and autoimmunity-associated protein termed nucleobindin. These results raise the possibility that the Cox isoenzymes may regulate intracellular signaling by both PG-dependent and PG-independent actions. Vascular endothelial cells are critical for the initiation and maintenance of the angiogenic response, a major process by which new blood vessels are formed in the adult (19Folkman J. Klagsburn M. Science. 1987; 235: 442-447Crossref PubMed Scopus (4045) Google Scholar). We originally cloned the Cox-2 cDNA from human umbilical vein endothelial cells and showed that Cox-2 expression is induced by various angiogenic factors, such as fibroblast growth factor-1, the tumor promoter PMA, and the inflammatory cytokine interleukin-1 (2Hla T. Ristimaki A. Appleby S. Barriocanal J.G. Ann. N. Y. Acad. Sci. 1993; 696: 197-204Crossref PubMed Scopus (159) Google Scholar, 20Hla T. Neilson K. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 7384-7388Crossref PubMed Scopus (1486) Google Scholar, 21Ristimaki A. Garfinkel S. Wessendorf J. Maciag T. Hla T. J Biol. Chem. 1994; 269: 11769-11775Abstract Full Text PDF PubMed Google Scholar). PMA, which inhibits growth of human umbilical vein endothelial cells and promotes angiogenesis in vitro as well as in vivo, induces an increase in Cox-2 mRNA expression, with minimal change in Cox-1 mRNA levels. Activation of endothelial cell Cox-2 expression results in the formation of various prostanoids, such as prostacyclin and PGE2, as well as HETEs (22Lopez S. Vila L. Breviario F. de Castellarnau C. Biochim. Biophys. Acta. 1993; 1170: 17-24Crossref PubMed Scopus (27) Google Scholar). Thus, Cox-2-derived prostanoids were thought to mediate endothelial cell functions including inhibition of thrombosis and regulation of vascular tone and permeability (23Murohara T. Horowitz J.R. Silver M. Tsurumi Y. Chen D. Sullivan A. Isner J.M. Circulation. 1998; 97: 99-107Crossref PubMed Scopus (469) Google Scholar). Indeed, PGE2 induces vascular endothelial cell growth factor expression and promotes angiogenesis (24Ben-Av P. Crofford L.J. Wilder R.L. Hla T. FEBS Lett. 1995; 372: 83-87Crossref PubMed Scopus (495) Google Scholar). Overexpression of Cox-2 is associated with chronic inflammatory diseases such as rheumatoid arthritis and solid tumor development (2Hla T. Ristimaki A. Appleby S. Barriocanal J.G. Ann. N. Y. Acad. Sci. 1993; 696: 197-204Crossref PubMed Scopus (159) Google Scholar,10Kawamori T Rao C.V. Seibert K. Reddy B.S. Cancer Res. 1998; 58: 409-412PubMed Google Scholar, 24Ben-Av P. Crofford L.J. Wilder R.L. Hla T. FEBS Lett. 1995; 372: 83-87Crossref PubMed Scopus (495) Google Scholar), both of which are characterized by enhanced angiogenesis. To study the effects of Cox-2 function, we attempted to derive endothelial and nonendothelial cells overexpressing Cox-2. Our efforts were routinely unsuccessful or resulted in clones that transiently expressed the transgene at low levels (17Narko K. Ristimaki A. MacPhee M. Smith E. Haudenschild C.C. Hla T. J. Biol. Chem. 1997; 272: 21455-21460Crossref PubMed Scopus (95) Google Scholar). Such cells grew at reduced rates, and loss of transgene expression resulted in growth enhancement. These anecdotal observations suggested that Cox-2 overexpression may confer a growth disadvantage. In this report, we studied this phenomenon in detail using a GFP-tagged Cox-2 chimeric protein. ECV-304 cells were obtained from Dr. Thomas Maciag (Maine Medical Center, Portland, ME). They were cultured in M199 medium (Cellgro, Mediatech) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone) and antimycotic-antibiotic mixture (Life Technologies, Inc). Bovine microvascular endothelial cells (Cell Systems) were grown in fibronectin-coated dishes in M199 supplemented with 20% fetal bovine serum. NIH 3T3 (ATCC CRL-6361), HEK 293 (ATCC CRL-1573), and COS-7 cells were grown in Dulbecco's modified Eagle's medium (Cellgro, Mediatech) plus 10% fetal bovine serum and antimycotic/antibiotic mixture. All plasmid-mediated transfections were performed on attached cells at 30–40% confluence using LipofectAMINE Plus (Life Technologies, Inc.) or NovaFECTOR (VennNova, Inc.). Indomethacin was purchased from Sigma, and NS-398 was purchased from Calbiochem. pcDNA/Neo and pcDNA/Zeo 3.1 were obtained from Invitrogen. Cox-2, Cox-2-S516Q, and S516M mutants (25Lecomte M. Laneuville O. Ji C. DeWitt D.L. Smith W.L. J. Biol. Chem. 1994; 269: 13207-13215Abstract Full Text PDF PubMed Google Scholar) in pOSML were kind gifts of Drs. David L. DeWitt and William Smith (Michigan State University). GFP-KDEL cDNA was generously provided by Dr. Mark Terasaki (UConn Health Center) in pSP64 (26Terasaki M. Jaffe L.A. Hunnicutt G.R. Hammer 3rd, J.A. Dev. Biol. 1996; 179: 320-328Crossref PubMed Scopus (88) Google Scholar) and subsequently cloned in the pcDNA/Zeo 3.1 expression vector. 9-N-Desaturase cDNA (27Heinemann F.S. Ozols J Mol. Biol. Cell. 1998; 9: 3445-3453Crossref PubMed Scopus (62) Google Scholar) cloned in pEGFP-N1 was kindly provided by Dr. Juris Ozols (UConn Health Center). Cox-2-GFP, S516Q-Cox-2-GFP (S516Q), and S516M-Cox-2-GFP (S516M) constructs were made by cloning the polymerase chain reaction-amplified GFP open reading frame (excluding the initiator methionine and the termination codon) into the BspEI site of the human Cox-2 cDNA (position 1854 (20Hla T. Neilson K. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 7384-7388Crossref PubMed Scopus (1486) Google Scholar)). The insertion did not interrupt the open reading frame and was in the C-terminal 18-amino acid Cox-2-specific region (Fig. 1 A). PGE2 release in the culture medium by cells stimulated for 15 min with 30 μm AA was used as an indicator of Cox-2 activity. PGE2 was determined by radioimmunoassay utilizing the method described by Mitchell et al. (28Mitchell J.A. Akarasereenont P. Thiemermann C. Flower R.J. Vane J.R. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 11693-11697Crossref PubMed Scopus (1568) Google Scholar). Prostaglandin synthesis was also assayed by TLC. Cells were incubated with 12.5 μm [1-14C]AA (Amersham Pharmacia Biotech) in serum-free medium. After 15 min at 37 °C, medium was collected and acidified with 1 m HCl, then subjected to lipid extraction with 6 volumes of chloroform/methanol (2:1 v/v) and separation on silica G TLC plates in the solvent system Iw (ethyl acetate:isooctane:acetic acid:water, 11:5:2:10) as described (29Bailey J.M. Muza B. Hla T. Salata K. J. Lipid Res. 1985; 26: 54-61Abstract Full Text PDF PubMed Google Scholar). TLC plates were then autoradiographed for 2–4 weeks. All eicosanoid standards were purchased from Cayman Inc. Radioactive eicosanoid bands were compared with cold standards visualized by staining with phosphomolybdic acid. Subconfluent cells were lysed in 200 μl of lysis buffer (1% Triton X-100, 150 mm NaCl, 10 mm Tris-HCl, pH 7.4, 1 mm EDTA, 1 mm EGTA, 0.2 mmNa3VO4, 0.5% Nonidet P-40, 0.1% SDS). Equal amounts of protein (100 μg/lane) were resolved by SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes (Protran; Schleicher & Schuell), and immunoblotted with an anti-GFP antibody. ECL detection reagents (Amersham Pharmacia Biotech) were used to visualize immunoblot signals. 48 h after transfection, cells were washed with PBS, trypsinized, fixed with 70% ethanol, and stored at −20 °C. Later cells were stained for 30 min at room temperature with a 20 μg/ml PI (Sigma) solution in PBS containing 0.1% Triton X-100 (Sigma) and 0.2 mg/ml DNase-free RNase A (Sigma). Cells were analyzed on a FACSCalibur flow cytometer (Becton and Dickenson). For each sample, at least 10,000 fluorescent cells were counted. ECV cells transfected with GFP or GFP-KDEL were sorted first in a FACS StarPlus cell sorter into green fluorescent and non-green fluorescent populations. After ethanol fixation, nuclear DNA was stained with PI, and cells were analyzed by FACS. After gating out cellular aggregates and debris, cell cycle distribution of fluorescent or nonfluorescent cells was analyzed using ModFitLT V2.0 software. For each condition, at least three different experiments were performed. Pulse labeling with BrdUrd was conducted in 3-cm glass-bottom dishes using the Roche Molecular Biochemicals labeling and detection kit, with the following modifications. BrdUrd concentration was 50 μm, cells were fixed in 70% ethanol in H2O, the incubation with the primary antibody was increased to 45 min, and the secondary anti-mouse antibody was conjugated with tetramethylrhodamine isothiocyanate. To visualize the nuclei, all samples were stained for 5 min with 1 μg/ml Hoechst 33342 (Sigma). For both green fluorescent and nonfluorescent populations, BrdUrd-positive cells (red nuclei) were counted and expressed as percentage of the total corresponding population (blue nuclei). Cells growing on glass coverslips or in glass-bottom 3-cm dishes were subjected to transient transfection with different variants of Cox-2 using lipofection reagents. 24–48 h later, cells were washed with PBS and fixed for 15 min with a 4% paraformaldehyde solution in PBS. For visualization of the nucleus, cells were stained for 5 min with 1 μg/ml Hoechst 33342 in PBS. Immunohistochemistry was carried out as follows. Cells were permeabilized for 5 min with 0.2% Triton X-100, washed with PBS, and incubated for 90 min with various primary antisera. After several washes, the secondary antibody, fluorescein isothiocyanate- or tetramethylrhodamine isothiocyanate-conjugated antibody was incubated with the sample for 30 min. If necessary, additional Hoechst 33342 staining was performed. All specimens were mounted in 80% glycerol and examined/photographed with a Zeiss-Axiovert 100 fluorescence microscope. All antibodies used for immunohistochemistry or Western blotting were purchased from Santa Cruz and Cayman. The Cox-2-GFP chimeric protein was constructed by insertion of the 27-kDa GFP polypeptide into the C-terminal 18-amino acid insert region of the Cox-2 polypeptide. This region, known to reside in the lumen of the ER, is dispensable for Cox-2 enzymatic activity (4Smith W.L. DeWitt D.L. Dixon F.J. Advances in Immunology. 62. Academic Press, Orlando, FL1996: 167-215Google Scholar, 25Lecomte M. Laneuville O. Ji C. DeWitt D.L. Smith W.L. J. Biol. Chem. 1994; 269: 13207-13215Abstract Full Text PDF PubMed Google Scholar). The GFP open reading frame, excluding the initiator methionine and the termination codon, was polymerase chain reaction-amplified and cloned into theBspEI site of the human Cox-2 cDNA (Fig.1 A). We next delineated the biochemical characteristics and the enzymatic function of the Cox-2-GFP polypeptide. As shown in Fig. 1 B, transfection of Cox-2-GFP into ECV-304 cells resulted in the production of a band at approximately 100 kDa, which was detected by the anti-GFP antibody. COS-7 cells transiently transfected with Cox-2 or Cox-2-GFP yielded comparable amounts of PGE2; this synthesis was completely inhibited by NS-398 (Fig. 2 A). These data suggest that the Cox-2-GFP polypeptide is enzymatically active. Incubation of Cox-1, Cox-2, or Cox-2-GFP-transfected ECV-304 cells with [14C]AA led to the release of prostanoids, which were further analyzed by TLC and autoradiography. As shown in Fig. 2 B, a similar pattern of prostanoids and HETEs was produced by all three transfections, suggesting that the Cox-2-GFP polypeptide is capable of coupling to isomerases in a manner similar to the wild-type protein. As shown previously, the human Cox-2 mRNA is highly unstable and does not accumulate to high levels in transfected cells (20Hla T. Neilson K. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 7384-7388Crossref PubMed Scopus (1486) Google Scholar). Cox-2-GFP expression level, as determined by enzyme activity measurements, was slightly higher than the native Cox-2. Fluorescence microscopic imaging of Cox-2-GFP-transfected cells was conducted to determine the subcellular localization of the Cox-2-GFP. As shown in Fig. 2 C, the Cox-2-GFP exhibited green fluorescence at the ER and the nuclear membrane, similar to the localization of the wild-type Cox-2 protein. Immunostaining of the Cox-2-GFP-transfected ECV-304 cells with anti-Cox-2 antibody, followed by detection with rhodamine-conjugated secondary antibodies, showed extensive colocalization of the green fluorescence and the Cox-2 epitopes, suggesting that Cox-2 and GFP are stable parts of the same protein (Fig. 2 D). Together, these data establish that the Cox-2-GFP is functionally indistinguishable from wild-type Cox-2. Next we determined the effect of Cox-2-GFP overexpression on cell cycle progression. ECV-304 cells were transiently transfected with the Cox-2-GFP, and cell cycle distribution was analyzed by DNA staining with PI followed by FACS analysis. We analyzed the cell cycle characteristics of GFP-positive (Cox-2-GFP expressing; Fig.3 A) as well as GFP-negative (Cox-2-GFP nonexpressing; Fig. 3 B) cells from the same plate by gating the high and low intensity green fluorescence signal in the analysis software. Cox-2-GFP expression into ECV-304 cells was associated with a significant decrease in S phase population (from 50% to 17%) and a 2-fold increase in G0/G1population (from 23% to 50%) compared with the nonfluorescent cells (Fig. 3 C). Cell cycle characteristics of GFP-negative cells are similar to those of untransfected or vector-transfected counterparts. To assess the specificity of G0/G1 arrest subsequent to the overexpression of Cox-2-GFP, we conducted several control experiments. First, we overexpressed the cytosolic GFP and ER-localized GFP-KDEL proteins in ECV-304 cells (27Heinemann F.S. Ozols J Mol. Biol. Cell. 1998; 9: 3445-3453Crossref PubMed Scopus (62) Google Scholar). As shown in Fig.3 C, GFP expression did not alter cell cycle distribution, whereas GFP-KDEL caused a minor decrease in S phase, from 55 to 41%. To determine the fate of cells transfected with Cox-2-GFP, ECV-304 green fluorescent cells were sorted with a FACS StarPlus cell sorter and maintained in culture for several days. Two distinct phenomena were observed. Some cells lost their fluorescence (implying a loss of Cox-2-GFP expression), and many fluorescent cells rounded and died. After 1 week in culture, less than 1% of the cells maintained their fluorescence. In no case was proliferation of Cox-2-GFP-positive cells seen, whereas GFP-positive colonies were routinely observed. These data strongly suggest that Cox-2-GFP overexpression in ECV-304 cells results in G0/G1 arrest, which leads to cell growth disadvantage and, ultimately, to cell death. We also overexpressed Cox-2-GFP in other cell lines such as HEK 293, COS-7, and NIH 3T3 cells. Cox-2-GFP expression caused a variable extent of growth arrest as indicated by a decrease in the population of cells in S phase (Fig. 3 D). For COS-7 cells, there was a 3-fold decrease in the percentage of cells in S phase, from 30 to 11%; for NIH 3T3, from 28 to 16%; and for HEK 293 cells, from 21% to 13%. Interestingly, HEK 293 and COS-7 cells exhibited a concomitant increase in the G2/M population. Fluorescence microscopic visualization of Cox-2-GFP-positive cells indicates an increase in binucleated cells, which appear as a part of the G2/M population in the FACS analysis. This is further documented in Fig.4. To validate the cell cycle data obtained by FACS analysis, we utilized the BrdUrd incorporation assay to determine the population of cells in the S phase. Quantitation of BrdUrd incorporation by Cox-2-GFP-positive and -negative cells is shown in Fig. 3 E. Both Cox-2 and Cox-2-GFP induced a similar degree of S-phase suppression in ECV-304 cells. Bovine microvascular endothelial cells exhibited a similar behavior with Cox-2-GFP overexpression but not in response to the overexpression of GFP-tagged 9-N-desaturase (an ER resident enzyme involved in fatty acid metabolism (27Heinemann F.S. Ozols J Mol. Biol. Cell. 1998; 9: 3445-3453Crossref PubMed Scopus (62) Google Scholar)). These data strongly suggest that overexpression of transfected Cox-2 enzyme results in growth arrest of a variety of cell types. We also observed that Cox-2-GFP overexpression is associated with changes in nuclear morphology. Untransfected ECV-304 cells exhibit primarily round nuclei. Occasionally, mitotic, kidney-shaped, or apoptotic nuclei are observed. ECV cells transfected with GFP-KDEL have a similar nuclear morphology (Fig. 4 A). In contrast, a large number of Cox-2-GFP positive cells exhibit prominent kidney-shaped, budding, or multilobular nuclei (Table I) or are binucleated (Fig. 4 B). Similar morphological changes were induced by Cox-2 transfection visualized with anti-Cox-2 antibody (Fig. 4 C). As shown in Table I, 44% of the Cox-2-GFP-positive cells undergo various degrees and types of nuclear morphological changes (including specific apoptotic nuclear morphology) compared with 11% in nonfluorescent cells. Out of the green fluorescent ECV cells, 12% are binucleated, compared with only 1.5% in the nonfluorescent cell population. These data suggest that overexpression of Cox-2-GFP or Cox-2 results in growth arrest as well as structural changes in the nuclear architecture, most likely due to defective nuclear envelope breakdown and/or cytokinesis. This may eventually result in increased cell death, which accompanies Cox-2-GFP overexpression. Similar to ECV Cox-2-GFP-transfected cells, COS-7 (Fig.4 D) and HEK 293 cells (Fig. 4 E) displayed various changes of nuclear morphology, in particular a very high frequency of binucleated cells. Such a phenotype is most likely generated by a defect in cytokinesis. This may explain the increase in G2/M population (as opposed to G0/G1) for COS-7 and HEK 293 cells transfected with Cox-2-GFP (Fig. 3 D).Table INuclear morphology changes induced in ECV-304 cells by transient transfectionExperimental conditionPopulationApoptotic nucleiAdvanced kidney shapeIncomplete lobulation (budding, shape changes)Binuclear or multiple lobesTotal abnormal nuclei%%%%%Cox-2-GFPGFP+6.5 ± 1.010.6 ± 2.814.7 ± 1.611.9 ± 1.843.7 ± 1.9GFP−3.6 ± 0.83.5 ± 1.22.5 ± 0.51.5 ± 0.911.1 ± 1.2GFP-KDELGFP+3.2 ± 0.35.0 ± 1.93.9 ± 2.92.8 ± 1.714.9 ± 0.8GFP−2.1 ± 0.34.1 ± 0.55.4 ± 1.60.4 ± 0.411.9 ± 2.2Cox-2-GFP + indomethacinGFP+6.5 ± 0.58.5 ± 2.416.9 ± 5.59.8 ± 2.642.0 ± 7.3GFP−4.2 ± 1.12.5 ± 0.63.5 ± 2.60.9 ± 0.411.1 ± 3.3Cox-2-GFP + NS-398GFP+4.4 ± 2.29.8 ± 2.115.9 ± 0.713.3 ± 1.043.4 ± 2.8GFP−4.1 ± 0.72.0 ± 0.62.4 ± 0.90.8 ± 0.39.2 ± 1.1ECV cells cultured in 6-well plates were transfected with Cox-2-GFP and GFP-KDEL. 48 h lated cells were fixed with 70% ethanol and stained with Hoechst 33342. Two groups of Cox-2-GFP-transfected cells were treated for 48 h with 2 μm indomethacin and 10 μm NS-398 previous to ethanol fixation. For each well, 10–15 random fields were photographed, and then the abnormal nuclei were counted and expressed as percentage of total number of cells (at least 100 cells were counted) for both populations. Cells expressing (GFP+) or not expressing (GFP−) the green transfectant protein are shown. Results are presented as mean ± S.D. of three independent duplicate transfections. Open table in a new tab ECV cells cultured in 6-well plates were transfected with Cox-2-GFP and GFP-KDEL. 48 h lated cells were fixed with 70% ethanol and stained with Hoechst 33342. Two groups of Cox-2-GFP-transfected cells were treated for 48 h with 2 μm indomethacin and 10 μm NS-398 previous to ethanol fixation. For each well, 10–15 random fields were photographed, and then the abnormal nuclei were counted and expressed as percentage of total number of cells (at least 100 cells were counted) for both populations. Cells expressing (GFP+) or not expressing (GFP−) the green transfectant protein are shown. Results are presented as mean ± S.D. of three independent duplicate transfections. We next determined whether prostanoid secretion by the Cox-2-GFP-transfected cells is necessary for the cell cycle arrest caused by Cox-2-GFP. As shown in Fig. 5 A, pretreatment of Cox-2-GFP-transfected cells with 2 μm indomethacin and 10 μm NS-398 for 48 h did not inhibit cell cycle arrest. Such treatment resulted in near complete (>95%) inhibition of prostanoid secretion of the Cox-2-GFP-transfected cells (Fig.2 A and data not shown). To further demonstrate the independence of prostanoid synthesis, we utilized two active-site mutants of Cox-2, initially characterized by Smith and co-workers (4Smith W.L. DeWitt D.L. Dixon F.J. Advances in Immunology. 62. Academic Press, Orlando, FL1996: 167-215Google Scholar,25Lecomte M. Laneuville O. Ji C. DeWitt D.L. Smith W.L. J. Biol. Chem. 1994; 269: 13207-13215Abstract Full Text PDF PubMed Google Scholar). These mutants, S516Q and S516M, mimic the aspirin-treated Cox-2 and do not produce any PGs (25Lecomte M. Laneuville O. Ji C. DeWitt D.L. Smith W.L. J. Biol. Chem. 1994; 269: 13207-13215Abstract Full Text PDF PubMed Google Scholar). However, the S516M mutant possesses a partial oxidative activity, resulting in the production of cell-associated 15-(R)-HETE (4Smith W.L. DeWitt D.L. Dixon F.J. Advances in Immunology. 62. Academic Press, Orlando, FL1996: 167-215Google Scholar, 25Lecomte M. Laneuville O. Ji C. DeWitt D.L. Smith W.L. J. Biol. Chem. 1994; 269: 13207-13215Abstract Full Text PDF PubMed Google Scholar). Western blot analysis with anti-GFP antibody on protein extracts from ECV-304 cells transfected with S516Q and S516M yielded an immunoreactive band at the same molecular weight as Cox-2-GFP (Fig. 5 A). TLC analysis of the lipids released into the culture medium confirmed the lack of cyclooxygenase activity in cells transfected with these two mutants (Fig. 5 B). Since 15-(R)-HETE is poorly secreted, we could not detect significant increases of the 15-(R)-HETE band in the medium. However, in some experiments, a radioactive band consistent with an esterified 15-HETE was observed near the solvent front (data not shown). As shown in Fig. 5, C andD, overexpression of S516M and S516Q mutants induced cell cycle arrest as determined by both FACS analysis and BrdUrd incorporation. These data unequivocally demonstrate that a nonprostanoid-dependent function of Cox-2 results in G0/G1 arrest of transfected cells. It is well established that the Cox-2 gene is growth factor-, cytokine-, and tumor promoter-inducible (1Dubois R.N. Abramson S.B. Crofford L. Gupta R.A. Simon L.S. Van De Putte L.B. Lipsky P.E. FASEB J. 1998; 12: 1063-1073Crossref PubMed Scopus (2225) Google Scholar, 2Hla T. Ristimaki A. Appleby S. Barriocanal J.G. Ann. N. Y. Acad. Sci. 1993; 696: 197-204Crossref PubMed Scopus (159) Google Scholar). Prostaglandin release by the Cox isoenzymes is limited by the self-inactivation or suicide mechanism of irreversible inactivation (1Dubois R.N. Abramson S.B. Crofford L. Gupta R.A. Simon L.S. Van De Putte L.B. Lipsky P.E. FASEB J. 1998; 12: 1063-1073Crossref PubMed Scopus (2225) Google Scholar, 2Hla T. Ristimaki A. Appleby S. Barriocanal J.G. Ann. N. Y. Acad. Sci. 1993; 696: 197-204Crossref PubMed Scopus (159) Google Scholar, 4Smith W.L. DeWitt D.L. Dixon F.J. Advances in Immunology. 62. Academic Press, Orlando, FL1996: 167-215Google Scholar). Therefore, de novo synthesis of Cox isoenzymes is required to restore the PG biosynthetic capacity. It is not known whether the sustained presence of the Cox-2 isoenzyme, which is observed during cytokine stimulation, is involved in regulation of cell growth. Indeed, treatment of vascular endothelial cells with the cytokine interleukin-1 or tumor promoter PMA results in concomitant increase in Cox-2 expression and inhibition of cell growth (21Ristimaki A. Garfinkel S. Wessendorf J. Maciag T. Hla T. J Biol. Chem. 1994; 269: 11769-11775Abstract Full Text PDF PubMed Google Scholar). Data in this report suggest that sustained overexpression of Cox-2 induces growth arrest of a variety of cell types. Interestingly, the ability of Cox-2 to induce growth arrest is independent of prostanoid secretion. This is consistent with the fact that interleukin-1 and PMA-induced endothelial cell growth arrest is not reversed by nonsteroidal anti-inflammatory drugs that block prostanoid synthesis (Ref. 21Ristimaki A. Garfinkel S. Wessendorf J. Maciag T. Hla T. J Biol. Chem. 1994; 269: 11769-11775Abstract Full Text PDF PubMed Google Scholar, and data not shown). These data suggest a novel mechanism of Cox-2 function. It is generally accepted that Cox-2 overexpression and activation of the relevant phospholipases result in the extracellular secretion of prostanoids such as PGE2 (1Dubois R.N. Abramson S.B. Crofford L. Gupta R.A. Simon L.S. Van De Putte L.B. Lipsky P.E. FASEB J. 1998; 12: 1063-1073Crossref PubMed Scopus (2225) Google Scholar, 2Hla T. Ristimaki A. Appleby S. Barriocanal J.G. Ann. N. Y. Acad. Sci. 1993; 696: 197-204Crossref PubMed Scopus (159) Google Scholar). However, the peroxidase activity of the Cox-2 isoenzyme may also play a role in signal transduction; for example, it was shown recently that the redox-sensitive transcription factor NFκB is regulated by the peroxidase activity of the Cox enzyme (16Munroe D.G. Wang E.Y. MacIntyre J.P. Tam S.S. Lee D.H. Taylor G.R. Zhou L. Plante R.K. Kazmi S.M. Bauerle P.A. Lau C. J. Inflamm. 1995; 45: 260-268PubMed Google Scholar). Thus, such a pathway may be involved in the growth arrest mechanism. Alternatively, interaction of Cox-2 polypeptide with cell cycle regulatory proteins in the ER or the nuclear envelope can result in the modulation of growth arrest. Indeed, Cox-2 was shown to bind to an apoptosis regulatory protein nucleobindin (18Ballif B.A. Mincek N.V. Barratt J.T. Wilson M.L. Simmons D.L. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 5544-5549Crossref PubMed Scopus (80) Google Scholar). Nevertheless, data in this report show unequivocally that Cox-2 overexpression induces G0/G1 growth arrest by an uncharacterized nonprostanoid-dependent signaling pathway. Further studies are required to define at a molecular level this novel mechanism of Cox-2 function and to assess its physiological relevance. We thank Drs. David DeWitt and William Smith of Michigan State University and Mark Terasaki and Juris Ozols of University of Connecticut Health Center for their kind gift of plasmids. We also acknowledge the help of Dr. Juris Ozols for critical reading of the manuscript and Dr. R. D. Berlin for helpful comments." @default.
• W2038260033 created "2016-06-24" @default.
• W2038260033 creator A5006724562 @default.
• W2038260033 creator A5036507892 @default.
• W2038260033 creator A5055366338 @default.
• W2038260033 creator A5057271826 @default.
• W2038260033 date "1999-11-01" @default.
• W2038260033 modified "2023-10-14" @default.
• W2038260033 title "Overexpression of Cyclooxygenase-2 Induces Cell Cycle Arrest" @default.
• W2038260033 cites W1536031017 @default.
• W2038260033 cites W1660326086 @default.
• W2038260033 cites W1967215636 @default.
• W2038260033 cites W1976372129 @default.
• W2038260033 cites W2005674716 @default.
• W2038260033 cites W2012810767 @default.
• W2038260033 cites W2013412524 @default.
• W2038260033 cites W2019328429 @default.
• W2038260033 cites W2023603090 @default.
• W2038260033 cites W2025284114 @default.
• W2038260033 cites W2032894856 @default.
• W2038260033 cites W2038410983 @default.
• W2038260033 cites W2043707891 @default.
• W2038260033 cites W2050717908 @default.
• W2038260033 cites W2051686420 @default.
• W2038260033 cites W2070688564 @default.
• W2038260033 cites W2089923844 @default.
• W2038260033 cites W2097895541 @default.
• W2038260033 cites W2127558096 @default.
• W2038260033 cites W2135992368 @default.
• W2038260033 cites W2148010796 @default.
• W2038260033 cites W2149233326 @default.
• W2038260033 cites W2156470937 @default.
• W2038260033 cites W4255042798 @default.
• W2038260033 doi "https://doi.org/10.1074/jbc.274.48.34141" @default.
• W2038260033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10567385" @default.
• W2038260033 hasPublicationYear "1999" @default.
• W2038260033 type Work @default.
• W2038260033 sameAs 2038260033 @default.
• W2038260033 citedByCount "110" @default.
• W2038260033 countsByYear W20382600332012 @default.
• W2038260033 countsByYear W20382600332013 @default.
• W2038260033 countsByYear W20382600332015 @default.
• W2038260033 countsByYear W20382600332016 @default.
• W2038260033 countsByYear W20382600332017 @default.
• W2038260033 countsByYear W20382600332018 @default.
• W2038260033 countsByYear W20382600332019 @default.
• W2038260033 countsByYear W20382600332021 @default.
• W2038260033 crossrefType "journal-article" @default.
• W2038260033 hasAuthorship W2038260033A5006724562 @default.
• W2038260033 hasAuthorship W2038260033A5036507892 @default.
• W2038260033 hasAuthorship W2038260033A5055366338 @default.
• W2038260033 hasAuthorship W2038260033A5057271826 @default.
• W2038260033 hasBestOaLocation W20382600331 @default.
• W2038260033 hasConcept C105696609 @default.
• W2038260033 hasConcept C1491633281 @default.
• W2038260033 hasConcept C181199279 @default.
• W2038260033 hasConcept C185592680 @default.
• W2038260033 hasConcept C2779689624 @default.
• W2038260033 hasConcept C29537977 @default.
• W2038260033 hasConcept C55493867 @default.
• W2038260033 hasConcept C86803240 @default.
• W2038260033 hasConcept C95444343 @default.
• W2038260033 hasConceptScore W2038260033C105696609 @default.
• W2038260033 hasConceptScore W2038260033C1491633281 @default.
• W2038260033 hasConceptScore W2038260033C181199279 @default.
• W2038260033 hasConceptScore W2038260033C185592680 @default.
• W2038260033 hasConceptScore W2038260033C2779689624 @default.
• W2038260033 hasConceptScore W2038260033C29537977 @default.
• W2038260033 hasConceptScore W2038260033C55493867 @default.
• W2038260033 hasConceptScore W2038260033C86803240 @default.
• W2038260033 hasConceptScore W2038260033C95444343 @default.
• W2038260033 hasIssue "48" @default.
• W2038260033 hasLocation W20382600331 @default.
• W2038260033 hasOpenAccess W2038260033 @default.
• W2038260033 hasPrimaryLocation W20382600331 @default.
• W2038260033 hasRelatedWork W1458434589 @default.
• W2038260033 hasRelatedWork W1972085353 @default.
• W2038260033 hasRelatedWork W1995228374 @default.
• W2038260033 hasRelatedWork W2119108207 @default.
• W2038260033 hasRelatedWork W2411653697 @default.
• W2038260033 hasRelatedWork W2420941028 @default.
• W2038260033 hasRelatedWork W2601331691 @default.
• W2038260033 hasRelatedWork W2919428694 @default.
• W2038260033 hasRelatedWork W3103815445 @default.
• W2038260033 hasRelatedWork W4296270000 @default.
• W2038260033 hasVolume "274" @default.
• W2038260033 isParatext "false" @default.
• W2038260033 isRetracted "false" @default.
• W2038260033 magId "2038260033" @default.
• W2038260033 workType "article" @default.